Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 231,906,345 papers from all fields of science
Search
Sign In
Create Free Account
VEGFR-2 DNA Vaccine VXM01
Known as:
VXM01
An orally available DNA cancer vaccine containing an attenuated strain of the bacterium Salmonella typhimurium encoding murine vascular endothelial…
Expand
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Імуногістохімічна характеристика маркерів неоангіогенезу у плоскоклітинному раку легені
M. Baudarbekova
2019
Corpus ID: 209990153
Цель работы – изучить особенности иммуногистохимической экспрессии VEGFR-2 и CD34…
Expand
2017
2017
VXM01 phase I study in patients with resectable progression of a glioblastoma.
W. Wick
,
A. Wick
,
+15 authors
M. Plattén
2017
Corpus ID: 57328361
2061Background: VXM01 consists of an attenuated Salmonella typhi Ty21a carrying a plasmid encoding for VEGFR-2. The bacterium is…
Expand
2016
2016
A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGF-receptor 2, in patients with advanced pancreatic cancer.
F. Schmitz-Winnenthal
,
L. Podola
,
+15 authors
P. Beckhove
2016
Corpus ID: 57213510
3091Background: VXM01 is an orally applied tumor vaccine based on live, attenuated salmonella bacteria carrying a eukaryotic…
Expand
2016
2016
Non-clinical safety and antitumor efficacy of live attenuated Salmonella typhimurium-based oral T-cell vaccines VXM01m, VXM04m and VXM06m
Sébastien Wieckowski
,
M. Springer
,
+10 authors
H. Lubenau
2016
Corpus ID: 78764454
2012
2012
Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced…
A. Niethammer
,
H. Lubenau
,
+13 authors
F. Schmitz-Winnenthal
BMC Cancer
2012
Corpus ID: 255803884
The investigational oral DNA vaccine VXM01 targets the vascular endothelial growth factor receptor 2 (VEGFR-2) and uses…
Expand
2012
2012
Angiogenic markers in canine lymphoma tissues do not predict survival times in chemotherapy treated dogs.
B. Wolfesberger
,
Z. Tonar
,
+7 authors
M. Kleiter
Research in Veterinary Science
2012
Corpus ID: 35490876
2008
2008
혈관 내피 성장인자 수용체-2 조절제에 대한 감수성을 판정하기 위한 방법 및 바이오마커
수잔 메리 갈브레이트
,
지저스 플라테로 파라다
2008
Corpus ID: 189449474
본 발명은 (a) 포유 동물에서 FGF2 농도를 측정하는 단계; 및 (b) 상기 샘플 중의 FGF2 농도를 기준과 비교하여 상기 샘플이 FGF2 양성 부류의 일원인지 FGF2…
Expand
2006
2006
Receptor VEGFR-2 – cel terapii kierowanej w chorobach nowotworowych VEGFR-2 receptor – target for anticancer therapy
Joanna Hucz
,
S. Szała
2006
Corpus ID: 59142939
wstawania nowych naczyń okołonowotworowych jest naczyniowo-śródbłonkowy czynnik wzrostu VEGF (ang. vascular endothelial growth…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE